Noam Harpaz, MD Email Noam Harpaz
- PROFESSOR | Pathology
- PROFESSOR | Medicine, Gastroenterology
- Anatomic Pathology
- Hospital Affiliation
- The Mount Sinai Hospital
Gastrointestinal pathology, general surgical pathology, and diagnostic immunopathology.
Anatomic & Clinical Pathology
- Anal Cancer
- Barrett's Esophagus
- Celiac Disease
- Colon Polyps
- Colorectal Cancer
- Colorectal Resection
- Crohn's Disease
- Esophageal Cancer
- Inflammatory Bowel Disease
- Ischemic Bowel Disease
- Peptic Ulcer
- Small Bowel Resection
- Squamous Cell Carcinoma
- Stomach Cancer
- Ulcerative Colitis
- Upper GI Endoscopy
PhD, Feinberg Graduate School Weizmann Institute of Science
, Hospital for Sick Children
MD, University of Miami School of Medicine
MD, Univ of Miami-School of Medicine
, Mount Sinai School of Medicine
, St. Mark's Hospital
Mount Sinai Hospital
Bansal R, Harpaz N, Itzkowitz SH, Ullman T, Matula S, Bodian C, Hossain S. Histological Inflammation is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort Study. Gastroenterology 2007; 133: 1099-1105.
Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Abreu MT, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Xu R. Toll-like receptor-4 (TLR4) promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133: 1869-1881.
Frank DN, St. Amand AL, Pace NR, Boedeker EC, Harpaz N, Feldman RA. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Nat Acad Sci 2007; 104: 13780-13788.
Harpaz N. Neoplastic Precursors of colorectal cancer in inflammatory bowel disease. Gastro Clin N Am 2007; 36: 901-926.
Harpaz N, Levi GS. Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol 2006; 30: 1022-1029.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Harpaz did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.